55 related articles for article (PubMed ID: 21350830)
41. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
42. Treatment of chronic lymphocytic leukemia with alemtuzumab: a review for nurses.
Lynn A; Williams ML; Sickler J; Burgess S
Oncol Nurs Forum; 2003; 30(4):689-94. PubMed ID: 12861328
[TBL] [Abstract][Full Text] [Related]
43. NCCN: New directions in chronic lymphocytic leukemia.
O'Brien S
Cancer Control; 2001; 8(6 Suppl 2):114-7. PubMed ID: 11760553
[No Abstract] [Full Text] [Related]
44. Minimal residual disease and survival in chronic lymphocytic leukemia.
Hillmen P
Clin Adv Hematol Oncol; 2005 Jul; 3(7):522-4. PubMed ID: 16167030
[No Abstract] [Full Text] [Related]
45. Future prospects for alemtuzumab (MabCampath).
Rai K; Hallek M
Med Oncol; 2002; 19 Suppl():S57-63. PubMed ID: 12180493
[TBL] [Abstract][Full Text] [Related]
46. Immunological effects and safe administration of alemtuzumab (MabCampath) in advanced B-cLL.
Kennedy B; Hillmen P
Med Oncol; 2002; 19 Suppl():S49-55. PubMed ID: 12180492
[TBL] [Abstract][Full Text] [Related]
47. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.
Osterborg A; Foà R; Bezares RF; Dearden C; Dyer MJ; Geisler C; Lin TS; Montillo M; van Oers MH; Wendtner CM; Rai KR
Leukemia; 2009 Nov; 23(11):1980-8. PubMed ID: 19626051
[TBL] [Abstract][Full Text] [Related]
48. T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
[TBL] [Abstract][Full Text] [Related]
49. Alemtuzumab and myelodysplasia: a story of love and hate (possible alemtuzumab-induced myelodysplastic changes).
Braester A; Akria L; Suriu C; Sonkin V
Acta Haematol; 2013; 129(3):185-6. PubMed ID: 23257842
[No Abstract] [Full Text] [Related]
50. Standard of care and novel treatments for chronic lymphocytic leukemia.
Seung AH
Am J Health Syst Pharm; 2010 Nov; 67(21):1813-24. PubMed ID: 20966144
[TBL] [Abstract][Full Text] [Related]
51. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
Fiegl M; Falkner F; Steurer M; Zojer N; Hopfinger G; Haslbauer F; Winder G; Voskova D; Andel J; Lang A; Brychtova Y; Mayer J; Greil R; Gastl G; ; ;
Ann Hematol; 2011 Sep; 90(9):1083-91. PubMed ID: 21350830
[TBL] [Abstract][Full Text] [Related]
52. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
53. Alemtuzumab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
[TBL] [Abstract][Full Text] [Related]
54. The evolving role of alemtuzumab in management of patients with CLL.
Faderl S; Coutré S; Byrd JC; Dearden C; Denes A; Dyer MJ; Gregory SA; Gribben JG; Hillmen P; Keating M; Rosen S; Venugopal P; Rai K
Leukemia; 2005 Dec; 19(12):2147-52. PubMed ID: 16239912
[TBL] [Abstract][Full Text] [Related]
55. Alemtuzumab: what is the secret to safe therapy?
Elter T; Hallek M; Montillo M
Clin Adv Hematol Oncol; 2011 May; 9(5):364-73. PubMed ID: 21685865
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]